A Randomized Double-Blind Phase-2 Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer.
Latest Information Update: 06 May 2022
At a glance
- Drugs Lonafarnib (Primary) ; Anastrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Schering-Plough
- 28 Jul 2009 Actual initiation date changed from Dec 2003 to Sep 2004 as reported by ClinicalTrials.gov.
- 28 Jul 2009 Actual initiation date changed from Dec 2003 to Sep 2004 as reported by ClinicalTrials.gov.
- 22 Dec 2008 Planned end date changed from 1 Dec 2008 to 1 Oct 2008 as reported by ClinicalTrials.gov.